Sugi Predict

Sugi Predict / Compounds / SCHEMBL30567693

SCHEMBL30567693

SCHEMBL30567693

CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CS)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CS)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](N)CCCCN)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)O)C(C)C

nearest known ligand 0.56

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
▸ GLP1R P43220 7/20 0.55
▸ GIPR P48546 7/20 0.55
▸ OPRD1 P41143 2/20 0.53
▸ CALCR P30988 4/20 0.53
▸ OPRM1 P35372 1/20 0.53
▸ GCGR P47871 1/20 0.53
▸ TFPI P10646 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29697094 0.92 CALCR (0.59) GLP1RGIPROPRD1CALCROPRM1
SCHEMBL31656525 0.92 GLP1R (0.56) GLP1RGIPROPRD1CALCROPRM1
SCHEMBL30567746 0.88 OPRD1 (0.55) GLP1RGIPROPRD1CALCRGCGR
SCHEMBL30567774 0.87 KEAP1 (0.51) GLP1RGIPROPRD1CALCROPRM1
SCHEMBL31000913 0.86 CALCR (0.66) GLP1RGIPROPRD1CALCROPRM1
SCHEMBL31042469 0.85 OPRD1 (0.54) GLP1RGIPROPRD1CALCROPRM1
SCHEMBL31688325 0.85 OPRD1 (0.53) OPRD1OPRM1
SCHEMBL29380135 0.85 OPRD1 (0.59) OPRD1OPRM1
SCHEMBL31683342 0.84 OPRD1 (0.51) OPRD1OPRM1
SCHEMBL29565233 0.84 OPRD1 (0.55) OPRD1OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240277841-A2 HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-08-22 — — US disclosed
US-20240024473-A1 HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE PURDUE RESEARCH FOUNDATION (US) 2024-01-25 — — US disclosed
CN-116601290-A Human chimeric antigen receptor neutrophils, compositions, kits and methods of use 普渡研究基金会 2023-08-15 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240277841-A2 HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE PBK, KIT, MYD88 GLP1R 2288/4885GIPR 947/4885OPRD1 3799/4885
US-20240024473-A1 HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE PBK, KIT, MYD88 GLP1R 2288/4885GIPR 947/4885OPRD1 3799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback